J9061 Injection, amivantamab-vmjw
Also known as: amivantamab, Rybrevant
Intravenous injection of amivantamab-vmjw, a bispecific monoclonal antibody targeting epidermal growth factor receptor (EGFR) and MET.
In Plain Language
dual-target cancer antibody; growth signal inhibitor
Clinical Context
Used to treat EGFR exon 20 insertion-mutated non-small cell lung cancer, blocking both EGFR and MET signaling.
RVU Information
CPT J9061 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9061?
CPT J9061 (Injection, amivantamab-vmjw) is a J Codes (Drugs) code. Intravenous injection of amivantamab-vmjw, a bispecific monoclonal antibody targeting epidermal growth factor receptor (EGFR) and MET.
How is J9061 administered?
CPT J9061 is administered by a healthcare provider, typically via injection or infusion. Used to treat EGFR exon 20 insertion-mutated non-small cell lung cancer, blocking both EGFR and MET signaling. It is used by Oncology, Pulmonary Oncology.
When is CPT J9061 used?
Used to treat EGFR exon 20 insertion-mutated non-small cell lung cancer, blocking both EGFR and MET signaling.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.